Literature DB >> 9727576

The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis.

J C Hendriks1, G A Satten, E J van Ameijden, H A van Druten, R A Coutinho, G J van Griensven.   

Abstract

OBJECTIVE: To estimate the incubation-period distribution (time from seroconversion to AIDS) accounting for death before an AIDS diagnosis (DBAD) in a cohort of injecting drug users (IDU) in Amsterdam, The Netherlands and to compare these estimates with those previously obtained from a contemporaneous study of homosexual and bisexual men in Amsterdam carried out using the same facilities.
DESIGN: Participants in a cohort study begun in Amsterdam at the end of 1985 have scheduled follow-up visits every 4 months. All participants of Dutch nationality and who had two or more follow-up visits before January 1996 from which CD4 measurements were available were included in this study. Data concerning AIDS diagnosis and death were verified through review of national and municipal registries.
METHODS: Because time of seroconversion was unknown for study participants and because IDU are at substantial risk for DBAD, we used a Markov model with CD4-based stages that allows for DBAD. The parameters in this model were estimated using the method of maximum likelihood and confidence intervals were calculated using bootstrap methods.
RESULTS: A total of 173 IDU (134 seroprevalent, 39 seroincident) made 1829 visits. Nearly 10% of the visits were non-consecutive. Forty-five IDU developed AIDS and 25 died without an AIDS diagnosis. We estimated that 24% [95% confidence interval (CI), 17-25%] of IDU die before an AIDS diagnosis. As a result, the median time from seroconversion to AIDS (10.5 years; 95% CI, 9.1-10.7 years) is considerably longer than the median time from seroconversion to death (8.3 years; 95% CI, 7.9-8.5 years). Conditional on survival to an AIDS diagnosis, the median time to AIDS is 8.2 years (95% CI, 7.7-8.7 years). The median survival time after a diagnosis of AIDS is estimated to be 1.0 years.
CONCLUSION: The high occurrence of DBAD in IDU has a considerable influence on estimates of the incubation-period distribution. Progression from seroconversion to death was faster in the IDU cohort than in a cohort of homosexual men in Amsterdam (median, 8.3 years and 9.6 years, respectively). However, progression to AIDS conditional on survival to an AIDS diagnosis seems to be similar in both the IDU cohort and in the cohort of homosexual men (median, 8.2 years and 8.3 years, respectively).

Entities:  

Mesh:

Year:  1998        PMID: 9727576     DOI: 10.1097/00002030-199812000-00017

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

1.  Community coverage and HIV prevention: assessing metrics for estimating HIV incidence through syringe exchange.

Authors:  Robert Heimer
Journal:  Int J Drug Policy       Date:  2008-01-18

2.  HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence.

Authors:  Hannah Fraser; Christinah Mukandavire; Natasha K Martin; Matthew Hickman; Myron S Cohen; William C Miller; Peter Vickerman
Journal:  Int J Epidemiol       Date:  2017-04-01       Impact factor: 7.196

3.  Evaluation of HIV incidence surveillance in New York City, 2006.

Authors:  Hemanth P Nair; Lucia V Torian; Lisa Forgione; Elizabeth M Begier
Journal:  Public Health Rep       Date:  2011 Jan-Feb       Impact factor: 2.792

4.  Methods for estimating HIV prevalence: A comparison of extrapolation from surveys on infection rate and risk behaviour with back-calculation for the Netherlands.

Authors:  H Houweling; S H Heisterkamp; L G Wiessing; R A Coutinho; J K van Wijngaarden; H J Jager
Journal:  Eur J Epidemiol       Date:  1998-10       Impact factor: 8.082

Review 5.  CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure.

Authors:  Afam A Okoye; Louis J Picker
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 6.  Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview.

Authors:  France Lert; Michel D Kazatchkine
Journal:  Int J Drug Policy       Date:  2007-07-17

7.  Injecting drug use is associated with a more rapid CD4 cell decline among treatment naïve HIV-positive patients in Indonesia.

Authors:  Hinta Meijerink; Rudi Wisaksana; Shelly Iskandar; Martin den Heijer; Andre J A M van der Ven; Bachti Alisjahbana; Reinout van Crevel
Journal:  J Int AIDS Soc       Date:  2014-01-03       Impact factor: 5.396

8.  HIV Disease Progression Among Antiretroviral Therapy Patients in Zimbabwe: A Multistate Markov Model.

Authors:  Zvifadzo Matsena Zingoni; Tobias F Chirwa; Jim Todd; Eustasius Musenge
Journal:  Front Public Health       Date:  2019-11-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.